FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs.

Development Programs

Anemia

Anemia
HIF-based technology

Developing therapeutics to selectively harness HIF-mediated response for red blood cell production

 
Chronic Kidney Disease

Chronic Kidney Disease
Anti-CTGF technology

Pioneering anti-CTGF therapy for treating chronic kidney disease and other complications of diabetes

 
Cytoprotection

Cytoprotection
HIF-based technology

Harnessing protective HIF biology for treating life-threatening conditions associated with hypoxic tissue injury

 
Fibrotic Disease

Fibrotic Disease
Anti-CTGF technology

Targeting CTGF to combat excessive and persistent scarring that leads to organ failure

Discovery Programs

FibroGen’s research team is committed to discovering novel therapies in areas of major unmet medical need. Our goal is to continue to provide pipeline candidates supported by rigorous data in well-characterized therapeutic settings.

Research Platforms

All of FibroGen’s therapeutic candidates have been internally developed based on FibroGen’s pioneering research in two important areas of biology, hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF).
 

Latest News

View all news
 

Upcoming Events

View all events
 


 
© 2013 FibroGen, Inc. All rights reserved.
HomeContact UsPrivacy PolicyTerms and ConditionsSite Map